Recombinant adenoviral-p53 intratumoral injection combined with radiotherapy for advanced nasopharyngeal carcinoma.
Phase of Trial: Phase III
Latest Information Update: 26 Jun 2012
At a glance
- Drugs Contusugene ladenovec (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 26 Jun 2012 Planned number of patients changed to 80.
- 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 21 May 2012 Actual end date (31 Oct 2011) added as reported by Chinese Clinical Trial Register record.